This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

PPAP

Extensively Studied

Historical-interest compound, not a current pick.

Aliases (8)

(-)-PPAP · (-)-1-Phenyl-2-propylaminopentane · 1-phenyl-2-propylamino-pentane · MK-306 · α · N-dipropylphenethylamine · DPPEA · phenylpropylaminopentane

TYPICAL DOSE

1-5 mg/kg

Daily

ROUTE

Oral (tablet)

Oral

CYCLE

No data. If using, default to weekday-on / week…

As prescribed

STORAGE

Room temp; original container

Room temp

Overview

What is PPAP?

PPAP (1-phenyl-2-propylaminopentane) is a synthetic phenylpropylaminopentane developed by Joseph Knoll (the inventor of selegiline) as a mesencephalic enhancer (catecholaminergic activity enhancer, "CAE"). It has no human pharmacokinetic data.

Key Benefits

In animal studies, reported to enhance impulse propagation in catecholaminergic neurons, improve mood and cognition, and extend lifespan in rats. Marketed as a more selective and non-amphetamine-like enhancer than selegiline; human evidence is essentially absent.

Mechanism of Action

Acts as a catecholaminergic activity enhancer (CAE), increasing impulse propagation-mediated release of dopamine, norepinephrine, and serotonin without releasing them from vesicles (unlike amphetamine). Mechanism is distinct from MAO inhibition.

▸Brand options3 known

MK-306N-dipropylphenethylamineDPPEA

StatusUnscheduled US (research chemical only). Controlled in Sweden (2020). Class A in UK. Schedule I (analog) in Canada.

Research Indications

Most Effective

The CAE concept (Knoll's central claim)

Knoll's late-career work centered on the idea that the brain's catecholaminergic neurons (dopamine and noradrenaline) have an "enhancer r…

Effective

What PPAP actually does

1. Impulse-coupled DA + NE release enhancement. When a catecholaminergic neuron fires, PPAP increases the magnitude of vesicular release …

Investigational

Why BPAP replaced PPAP

Knoll's lab synthesized 65+ analogs. BPAP (1-(benzofuran-2-yl)-2-propylaminopentane, 1999) replaced PPAP's phenyl ring with a benzofuran.…

Peptide Interactions

modafinil:

Synergistic

Different mechanisms — modafinil raises orexin/histamine + weak DAT inhibition; PPAP enhances impulse-coupled DA/NE release + (per 2025 data) DAT inhibition.…

bromantane:

Synergistic

Bromantane upregulates DA synthesis (substrate-side); PPAP enhances release per impulse (output-side). Mechanistically clean — synthesis + release work on di…

selegiline:

Avoid

NEVER COMBINE. Both target the CAE/TAAR1 mechanism. Adding PPAP to selegiline (especially at any tier above 5 mg oral selegiline) produces overlapping CAE dr…

bpap:

Avoid

Same family, redundant. Pick one.

MAOIs (phenelzine, tranylcypromine, rasagiline, linezolid, methylene blue):

Avoid

Hypertensive crisis + serotonin syndrome risk. PPAP itself doesn't inhibit MAO, but raising synaptic catecholamines in the presence of MAO-A inhibition is th…

SSRIs / SNRIs:

Avoid

Theoretical serotonin syndrome risk via the catecholamine-serotonin crosstalk pathways. PPAP itself is catecholamine-selective (not serotonergic) so this ris…

Amphetamines / methylphenidate / cocaine:

Avoid

Additive DAT load (per 2025 reuptake data) + additive sympathomimetic activation. Avoid.

Tramadol, meperidine, methadone, DXM:

Avoid

Same serotonergic-opioid cautions as for any monoamine-active drug.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Onset
30-60 min sublingual / oral
Peak
~2-3 hours

Side Effects & Safety 7

Side Effects

1Wide therapeutic index reported — wider than amphetamine in the assays Knoll used.
2High doses (50 mg/kg in rats) produced motility *inhibition* rather than activation — opposite of amphetamine and consistent with self-limiting CAE pharmacology rather than runaway monoamine release.
3No reports of stereotypies, hyperthermia, or DA-neurotoxicity at therapeutic doses. (Caveat: stereotypy + neurotoxicity are dose-dependent — thorough chronic-dose toxicology in primates was never done.)
4Anxiety at higher doses (40-50 mg). Reported by multiple users. Consistent with elevated NE tone.
5Insomnia if PM-dosed. Standard for any DA/NE-enhancing compound — keep dosing AM.
6Liver concern raised in forums but attributed (probably correctly) to BPAP, not PPAP. PPAP-specific hepatotoxicity is undocumented.
7No reports of dependence or withdrawal. Animal data and the impulse-coupled mechanism both predict low abuse liability — but this is a prediction, not a confirmed human safety claim.

When to Stop

Serotonin syndrome risk if combined with MAOIs, SSRIs, or other serotonergic drugs. Theoretical, not documented for PPAP specifically.
Hypertensive episodes with sympathomimetic stacking. Theoretical.
The "safe in humans" claim cannot be made — there is no human safety database. Anyone using PPAP is functionally a Phase 0 subject.
First few doses: monitor BP + HR for ≥2 hours post-dose. CAE compounds raise NE tone; individual response varies.
Sleep effects: track for ~2 weeks. If even 9 AM dosing is wrecking sleep, drop the compound — there's nothing in the data to justify pushing through.